GlaxoSmithKline PLC Current Deferred Revenue Over Time
| GSK Stock | USD 33.70 0.35 1.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out GlaxoSmithKline PLC Performance and GlaxoSmithKline PLC Correlation. GlaxoSmithKline |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.54 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare GlaxoSmithKline PLC ADR and related stocks such as Novartis AG ADR, AstraZeneca PLC ADR, and Roche Holding Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVS | 0.0 | 70 M | 71 M | 70 M | 329 M | 385 M | 287 M | 305 M | 236 M | 114 M | 56 M | 123 M | 123 M | 98 M | 135.9 M |
| AZN | (3.2 B) | (6.8 B) | (6.5 B) | (7.9 B) | (8.4 B) | (8.2 B) | (7.5 B) | (8 B) | (11.1 B) | 28 M | 1.6 B | 1 B | 181 M | 149 M | 156.4 M |
| BMY | 4.2 B | 337 M | 825 M | 756 M | 1.2 B | 1 B | 762 M | 83 M | 172 M | 4.5 B | 3.6 B | 3.7 B | 1.3 B | 8.4 B | 8.8 B |
| AMGN | (88 M) | (88 M) | (88 M) | (88 M) | (88 M) | (88 M) | (88 M) | (88 M) | (88 M) | (88 M) | (88 M) | (88 M) | (88 M) | (79.2 M) | (83.2 M) |
| MRK | 3.4 B | 1 B | 1 B | 1 B | 1 B | 1 B | 1 B | 1 B | 1 B | 1 B | 1 B | 4.6 B | 4.6 B | 5.3 B | 6.6 B |
| ABBV | (3.7 B) | (3.7 B) | (3.7 B) | (3.7 B) | (3.7 B) | (3.7 B) | (3.7 B) | (3.7 B) | (3.7 B) | (3.7 B) | (3.7 B) | (3.7 B) | (3.7 B) | (3.3 B) | (3.5 B) |
| GILD | 4 M | 74.7 M | 103.2 M | 110.6 M | 134 M | 440 M | 202 M | (3.6 B) | (2.3 B) | (2.3 B) | (2.3 B) | (2.3 B) | (2.3 B) | (2.1 B) | (2 B) |
| JNJ | 4.1 B | 2.6 B | 3.1 B | 3.6 B | 3.6 B | 5.5 B | 6.1 B | 1.9 B | 7.6 B | 7.8 B | 3 B | 3 B | 3 B | 3.4 B | 4.5 B |
| SNY | 4 M | 4 B | 3.8 B | 3.7 B | 3.7 B | 4.2 B | 4.2 B | 4.1 B | 4.2 B | 3.8 B | 252 M | 319 M | 264 M | 597 M | 567.1 M |
| BIIB | 3.8 M | (186.4 M) | 148 M | 172.7 M | 120.9 M | 55.7 M | 148.9 M | 68.2 M | (530.8 M) | (530.8 M) | (83.2 M) | (589.2 M) | (97.2 M) | 1.1 B | 1.2 B |
GlaxoSmithKline PLC ADR and related stocks such as Novartis AG ADR, AstraZeneca PLC ADR, and Roche Holding Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| GlaxoSmithKline PLC ADR | GSK |
| Classification | Healthcare |
| Location | United Kingdom |
| Exchange | New York Stock Exchange |
USD 33.7
Check out GlaxoSmithKline PLC Performance and GlaxoSmithKline PLC Correlation. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
GlaxoSmithKline PLC technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.